Recommended public offer to the shareholders and warrant holders of Sensidose AB (SE) by Navamedic ASA (NO) – SEK 103 million

Carnegie acted as financial advisor to Navamedic in the recommended public offer to the shareholders in Sensidose to tender all shares and TO 1 warrants in Sensidose to Navamedic at a price of SEK 8.50 in cash per share and SEK 0.60 in cash per TO 1 warrant. Navamedic is a Nordic pharma company and a reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Sensidose is a pharmaceutical company that has developed a system for individualized dosing of tablets, a medical treatment using a dosing device pre-programmed for the patient.